Clario

At Clario, we understand the critical role that advanced imaging technologies play in evaluating new therapies for Multiple Sclerosis (MS). From Magnetic Resonance Imaging (MRI) to specialized modalities like Diffusion-Magnetic Resonance Imaging (DMRI) and Magnetization Transfer Imaging (MTI), our comprehensive solutions provide valuable insights into neurodegeneration. These imaging techniques are indispensable for long-term studies and offer precise and reliable data to support the development of effective #MS treatments. With over 50 years of imaging expertise, we're dedicated to helping sponsors assess the efficacy and safety of potential new MS treatments. If you missed our webinar on Advancing MS Clinical Trials, watch the recording and discover how advanced medical imaging, precision motion analysis, and robust eCOA strategy data can bring more accurate, reliable, and patient-focused results in MS studies. ➡ https://lnkd.in/db7xgH7D #MultipleSclerosis #MSstudies #ClinicalTrials #Medicalimaging #eCOA

📣 Are you attending #ObesityWeek2024 in San Antonio, Texas? Be sure to stop by eCOA Scientist Jessica Emerson's poster presentation on November 4 from 2:30- 3:30 pm CST. Dr Emerson will discuss "Patient Reported Outcomes in Diabetes and Obesity Trials using Natural Language Processing." Looking forward to seeing you there! 👋 To learn more, visit: https://lnkd.in/d2mXa2kR ObesityWeek®

We’re delighted to announce the opening of Clario’s new office in Leuven, Belgium! 🎉 Following our acquisition of ArtiQ in April, the two teams will use this new space to exchange ideas, collaborate in person, and strengthen their bonds as they work towards our shared mission. With the ribbon officially cut by our EVP and GM of Digital Physiology, Ellen Street (Conway), and our Chief AI Officer, Marko Topalovic, Clario's Belgium team now has a dedicated environment to foster innovation. Here’s to new beginnings and even greater achievements in transforming clinical trials to enhance patient outcomes through cutting-edge solutions! 🎊

Parkinson's disease is widely considered a movement-related disease, characterized by gait impairments, slow movements, tremors, postural instability, and rigidity. Based on the complexities of the disease, patients and caregivers understandably have high expectations for treatment. Before starting a clinical trial, they frequently ask: ▫Is the drug safe for my health? ▫Is it proven effective? ▫Will it improve my overall well-being? ➡ Visit our website to see how Clario can help you address these critical questions with confidence by leveraging our scientific, operational, and regulatory experience. https://lnkd.in/d9tCjbSt #Parkinsons #ParkinsonsResearch #ClinicalTrials #ClarioNeuroscience

#Obesity affects over 1 billion people worldwide, and with the rise in #ClinicalTrials for therapies like GLP-1 agonists, it's more important than ever to ensure a holistic approach to safety and efficacy assessments. These therapies are being evaluated for their impact on cardiovascular and metabolic effects, mental health impact, and more. 📣 Join us for our upcoming webinar, 'Optimizing Obesity Trials: Integrating Diverse Endpoints to Holistically Assess Safety and Efficacy of GLP-1 Agonists and Beyond.' Hear from Clario experts on how to design obesity trials that incorporate multi-disciplinary endpoints and generate robust data. 📅 November 12, 2024 🕒 11:00 AM – 12:00 PM Speakers: ▪Todd Rudo, M.D., Chief Medical Officer ▪Paul Strumph, M.D., Diabetes & Metabolism Key Opinion Leader ▪Fabian Chen, M.D., VP and Deputy CMO, Cardiology ▪Mark W. Tengowski, DVM, M.S., Ph.D., Director Medical & Scientific Affairs, Medical Imaging ➡ Don’t miss out—register now! https://lnkd.in/diqaa6tn

🎉 We’re excited to announce that Clario will be a sponsor and attendee at the CTAD Clinical Trials on Alzheimer's Disease Conference in Madrid! This annual event brings together global leaders and innovators in #Alzheimer’s research, and we’re honored to be part of it. 🗓 Join our #neuroscience team in person from October 29 – November 1 in Madrid, or connect with us on the #CTAD24 digital platform. Don’t miss Dr. Prateek Verma, MD, Clario's Director of eCOA and Consulting, as he will present on November 1. He will discuss Cognitive Assessment and Wearable Sensor-Based Gait and Balance Assessment in Alzheimer’s Disease and Mild Cognitive Impairment studies. ➡ https://lnkd.in/dzXyphm5 We look forward to seeing you there! 👋 #ClarioNeuroscience

📣 Are you attending the Outsourcing in Clinical Trials New England event? Be sure to join our VP of R&D Imaging, Brian Wehrle, for an insightful session on 'Accelerating Clinical Trials with Meaningful AI.' Learn how to identify #AI opportunities, and explore real-life examples of AI speeding up #ClinicalTrials. And don’t forget to visit us at Booth #43 to connect with our team and discover more about our innovative solutions for clinical trials! ➡ https://lnkd.in/d5zUC6XE See you in Boston! 👋

Parkinson’s disease affects over 8.5 million people worldwide, making it the second most common neurodegenerative disease after Alzheimer’s disease. Could your Parkinson’s drug be the key to a better future? Clario's clinical trial endpoint solutions are here to help. We support drug development through innovative assessments of efficacy, safety, and patient quality of life. ➡ Visit our website and explore our Parkinson's solutions: https://lnkd.in/d9tCjbSt #Parkinsons #ParkinsonsResearch #ClinicalTrials #CRO #Biotech  #ClarioNeuroscience

Clario's SVP and General Counsel, Lauren Misztal, recently spoke with the multinational law firm, Sidley Austin LLP, about the ethical use of Artificial Intelligence in clinical trials. In an insightful interview, Lauren discusses how our #AI models are advancing #ClinicalTrials, reducing the burden on patients and sites, and why Clario follows the highest ethical standards when developing and implementing Artificial Intelligence solutions. ➡ Check out the interview here https://lnkd.in/drsNchDM

📣Don’t miss out! Join us tomorrow for the webinar, "Psychiatric Drug Development: Digital Endpoint Solutions to Extract the Most Value from Your Clinical Study." 💊 Discover how innovative solutions like eCOA rater training, placebo response training, advanced medical imaging, and patient-centric cardiac monitoring are transforming psychiatric drug development. Learn how these advancements can improve trial accuracy and enhance patient outcomes. Hear from Clario's experts: ▫️Todd Rudo, EVP & Chief Medical Officer ▫️Prateek Verma, MD, Director, eCOA Science & Consulting ▫️David Scott, PhD, VP, Medical & Scientific Affairs, Neuroscience ▫️Alain GAY, Senior Cardiologist Register now: https://hubs.li/Q02TqD9m0 #ClinicalTrials #DrugDevelopment #Psychiatry